Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model
Hideki Furuya,Owen T. M. Chan,Ian Pagano,Chengjun Zhu,Nari Kim,Rafael Peres,Kanani Hokutan,Sarah Alter,Peter Rhode,Charles J. Rosser
DOI: https://doi.org/10.1186/s12967-019-1778-6
IF: 8.44
2019-01-17
Journal of Translational Medicine
Abstract:<h3 class="a-plus-plus">Abstract</h3> <span class="a-plus-plus abstract-section id-a-sec1"> <h3 class="a-plus-plus">Background</h3> <p class="a-plus-plus">We set out to determine if the administration of subcutaneous (SQ) ALT-803 was non-inferior to standard intravesical BCG treatment in a carcinogen induced mouse (C57BL/6J) bladder cancer model.</p> </span> <span class="a-plus-plus abstract-section id-a-sec2"> <h3 class="a-plus-plus">Methods</h3> <p class="a-plus-plus">Using this well-established carcinogen induced mouse model, we studied the effects of various dosing schemas of ALT-803 (SQ alone, SQ with intravesical BCG, intravesical alone, intravesical with intravesical BCG) compared to intravesical BCG alone (positive control) and PBS (negative control). The non-inferiority margin for the difference in bladder weight, as a surrogate for tumor mass, was defined as 7%.</p> </span> <span class="a-plus-plus abstract-section id-a-sec3"> <h3 class="a-plus-plus">Results</h3> <p class="a-plus-plus">All treatment groups (i.e., ALT-803 SQ alone, ALT-803 SQ with intravesical BCG, ALT-803 intravesical alone, ALT-803 intravesical with intravesical BCG and intravesical BCG alone) demonstrated a significant reduction in tumor burden as evident by bladder weights and H&E stain (p < 0.005). Non-inferiority tests between the intravesical BCG alone group and the additional treatment groups showed that SQ ALT-803 alone (p = 0.04) and BCG plus SQ ALT-803 (p = 0.009) were non-inferior to intravesical BCG alone. In this model, we did not see an appreciable infiltration of CD4<sup class="a-plus-plus">+</sup> T, CD8<sup class="a-plus-plus">+</sup> T or CD161/KLRB1<sup class="a-plus-plus">+</sup> natural killer (NK) cells in the bladder/tumor. When assessing peripheral blood mononuclear cells, SQ ALT-803 alone resulted in a robust induction of CD8<sup class="a-plus-plus">+</sup> T cells (p < 0.01), NKG2D<sup class="a-plus-plus">+</sup> NK cells (p < 0.005) and CD3<sup class="a-plus-plus">+</sup>/NKG2D<sup class="a-plus-plus">+</sup> NKT cells (p < 0.005) compared to other groups, while in splenic tissue, SQ ALT-803 alone resulted in a robust induction of CD3<sup class="a-plus-plus">+</sup>/NKG2D<sup class="a-plus-plus">+</sup> NKT cells (p < 0.005) compared to other groups.</p> </span> <span class="a-plus-plus abstract-section id-a-sec4"> <h3 class="a-plus-plus">Conclusion</h3> <p class="a-plus-plus">Subcutaneous ALT-803 treatment alone or in combination with intravesical BCG was well tolerated and was not inferior to intravesical BCG alone. CD8<sup class="a-plus-plus">+</sup> T, NKG2D<sup class="a-plus-plus">+</sup> NK and CD3<sup class="a-plus-plus">+</sup>/NKG2D<sup class="a-plus-plus">+</sup> NKT cell induction along with induction of key cytokines remain steadfast mechanisms behind ALT-803. The enhanced therapeutic index seen with BCG and ALT-803, administered SQ or intravesically, provides a powerful justification for the further development of these regimens.</p> </span>
medicine, research & experimental